GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (FRA:22Z) » Definitions » EV-to-EBITDA

Zealand Pharma AS (FRA:22Z) EV-to-EBITDA : -47.57 (As of Dec. 11, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zealand Pharma AS's enterprise value is €6,096.42 Mil. Zealand Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-128.17 Mil. Therefore, Zealand Pharma AS's EV-to-EBITDA for today is -47.57.

The historical rank and industry rank for Zealand Pharma AS's EV-to-EBITDA or its related term are showing as below:

FRA:22Z' s EV-to-EBITDA Range Over the Past 10 Years
Min: -94.74   Med: -12.81   Max: 8.02
Current: -47.57

During the past 13 years, the highest EV-to-EBITDA of Zealand Pharma AS was 8.02. The lowest was -94.74. And the median was -12.81.

FRA:22Z's EV-to-EBITDA is ranked worse than
100% of 447 companies
in the Biotechnology industry
Industry Median: 9.29 vs FRA:22Z: -47.57

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-11), Zealand Pharma AS's stock price is €101.30. Zealand Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-2.247. Therefore, Zealand Pharma AS's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Zealand Pharma AS EV-to-EBITDA Historical Data

The historical data trend for Zealand Pharma AS's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS EV-to-EBITDA Chart

Zealand Pharma AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.93 -12.19 -7.91 -12.08 -30.77

Zealand Pharma AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.35 -30.77 -72.47 -87.97 -51.64

Competitive Comparison of Zealand Pharma AS's EV-to-EBITDA

For the Biotechnology subindustry, Zealand Pharma AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's EV-to-EBITDA falls into.



Zealand Pharma AS EV-to-EBITDA Calculation

Zealand Pharma AS's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=6096.424/-128.166
=-47.57

Zealand Pharma AS's current Enterprise Value is €6,096.42 Mil.
Zealand Pharma AS's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-128.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zealand Pharma AS  (FRA:22Z) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Zealand Pharma AS's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=101.30/-2.247
=At Loss

Zealand Pharma AS's share price for today is €101.30.
Zealand Pharma AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.247.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Zealand Pharma AS EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zealand Pharma AS's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zealand Pharma AS Business Description

Traded in Other Exchanges
Address
Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Zealand Pharma AS Headlines

No Headlines